How FDA scientists opposed the Trump administration’s push for easier access to peptides

FDA scientific staff members opposed a Trump administration plan to increase access to unproven injectable peptides favored by HHS Secretary Robert F. Kennedy Jr. These peptides are promoted within the wellness industry for energy, injury healing, and muscle growth. According to six sources, FDA staffers had limited input in drafting the policy and warned that the move could undermine the agency's mission. The document recently underwent White House regulatory review before being posted online by the HHS.